Brian D. Rankin
Calgary, AB, Canada
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 41 publications
Prevalence of Regulatory Safety Risk Factors Among Adolescents and Adults With Atopic Dermatitis Receiving Advanced Systemic Therapies: An International Real-World Study.
Journal: International journal of dermatology
Published: July 02, 2026
Real-World Effectiveness and Safety of Deucravacitinib for Adult Patients with Plaque Psoriasis: A 16-Week Multicenter Retrospective Study of Monotherapy and Combination Therapy.
Journal: Journal of cutaneous medicine and surgery
Published: June 05, 2026
Application of Real-World Effectiveness Outcomes of Upadacitinib to Canadian Treat-to-Target Criteria in Atopic Dermatitis: A Retrospective Multicenter Analysis of 1-Year Data.
Journal: Journal of the American Academy of Dermatology
Published: April 20, 2026
Carcinoma en cuirasse mimicking dermatomal herpes zoster: A case report.
Journal: SAGE open medical case reports
Published: March 12, 2026
OSCEai dermatology: augmenting dermatologic medical education with Large Language Model GPT-4.
Journal: Canadian medical education journal
Published: January 26, 2026
Epidemiology of Consult Requests to the Dermatological Service in Calgary, Alberta, Canada: A Retrospective Study.
Journal: Journal of cutaneous medicine and surgery
Published: December 26, 2025
Clinical Trial Eligibility in Atopic Dermatitis: Data from a Large Real-World International Cohort.
Journal: Dermatology and therapy
Published: November 14, 2025
Five-year real-world drug survival of dupilumab in patients with atopic dermatitis: A multicenter retrospective study.
Journal: Journal of the American Academy of Dermatology
Published: June 18, 2025
Real-World Effectiveness and Safety of Dupilumab, Tralokinumab, and Upadacitinib in Patients with Atopic Dermatitis: A 52-Week International, Multicenter Retrospective Cohort Study.
Journal: Dermatology and therapy
Published: April 05, 2025
Real-World Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-23 Inhibitors: A Multicenter Retrospective Study.
Journal: American journal of clinical dermatology
Published: January 12, 2025
Response to Potestio et al., "Comment on Real-world experience of bimekizumab for plaque psoriasis in adult patients with prior exposure to interleukin-17 inhibitors: A 16-week multicenter retrospective review".
Journal: Journal of the American Academy of Dermatology
Published: November 19, 2024
Last Updated: 09/26/2026